Clinical Research Directory
Browse clinical research sites, groups, and studies.
IB-T101 Injection for Treatment of Patients with Advanced Clear Cell Renal Cell Carcinoma
Sponsor: Grit Biotechnology
Summary
This is an open label, single center, dose escalation, and dose extension IIT study aimed at evaluating the safety, efficacy, and pharmacokinetics of IB-T101 in adult patients with advanced clear renal cell carcinoma
Official title: A Phase I, Open Label, Single Center Study Evaluating the Safety and Efficacy of IB-T101 Injection for Treatment of Patients with Advanced Clear Cell Renal Cell Carcinoma
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
12
Start Date
2024-12-06
Completion Date
2027-12-07
Last Updated
2025-02-17
Healthy Volunteers
No
Conditions
Interventions
IB-T101 injection
IB-T101 injection to treat advanced clear renal cell carcinoma
Locations (1)
Tongji hospital, Huazhong University of Science and Technology
Wuhan, Hubei, China